Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Dr Reddy’s Laboratories invests Rs 565 crore in Russian subsidiary, acquiring 45.19% stake for working capital needs.

Dr Reddy's Laboratories share price gained almost 3% in the morning trades on Thursday post Q1 results that were declared ...

Emkay Global has raised Dr Reddy’s target price to ₹1,150 from ₹1,050 but maintained a ‘Reduce’ rating after a weak Q1FY26 ...

Dr Reddy’s kicks off India’s big pharma earnings season with a narrow profit miss. The pharmaceutical company reported a ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

Erez Israeli, CEO of Dr Reddys Laboratories, said that the company has no plans to shift manufacturing to the US unless it ...

Dr. Reddy’s Laboratories ( NYSE: RDY) is preparing to launch a generic version of semaglutide, the active ingredient in Novo ...

Hyderabad: Despite clocking its highest-ever quarterly revenues during the first quarter ended June 30, pharma major Dr Reddy ...